Patents by Inventor Michael J. Munchhof

Michael J. Munchhof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970485
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: April 30, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • Patent number: 11964968
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: April 23, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
  • Publication number: 20230312544
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Application
    Filed: February 6, 2023
    Publication date: October 5, 2023
    Inventors: Erin D. ANDERSON, Steven W. ANDREWS, Kevin R. CONDROSKI, Thomas C. IRVIN, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan MCKENNEY, Michael J. MUNCHHOF, Michael B. WELCH
  • Publication number: 20230265085
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Application
    Filed: October 19, 2022
    Publication date: August 24, 2023
    Inventors: Gabrielle R. KOLAKOWSKI, Erin D. ANDERSON, Steven W. ANDREWS, Christopher Pierre Albert Jean BOLDRON, Kevin R. CONDROSKI, Thomas C. IRVIN, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Johnathan Alexander MCLEAN, Tiphaine MOURET, Michael J. MUNCHHOF, Thomas Pierre Dino PANCALDI, Michael Alexander PILKINGTON-MIKSA, Marta PINTO
  • Patent number: 11697647
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: July 11, 2023
    Assignee: Eli Lilly and Company
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • Patent number: 11613533
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 28, 2023
    Assignee: Eli Lilly and Company
    Inventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
  • Publication number: 20220144816
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Inventors: Gabrielle R. Kolakowski, Erin D. ANDERSON, Steven W. Andrews, Christopher Pierre Albert Jean BOLDON, Kevin R. CONDROSKI, Thomas C. IRVIN, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Johnathan Alexander MCLEAN, Tiphaine MOURET, Michael J. MUNCHHOF, Thomas Pierre Dino PANCALDI, Michael Alexander PILKINGTON-MIKSA, Marta PINTO
  • Publication number: 20210363140
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 25, 2021
    Inventors: Erin D. ANDERSON, Steven W. ANDREWS, Kevin R. CONDROSKI, Thomas C. IRVIN, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan MCKENNEY, Michael J. MUNCHHOF, Michael B. WELCH
  • Patent number: 8431597
    Abstract: The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: April 30, 2013
    Assignee: Pfizer Inc.
    Inventors: Michael J. Munchhof, Lawrence A. Reiter, Susan D. La Greca, Christopher S. Jones, Qifang Li
  • Publication number: 20130072427
    Abstract: Compounds of formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
    Type: Application
    Filed: July 22, 2010
    Publication date: March 21, 2013
    Inventors: Cristiano Guimaraes, Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson
  • Publication number: 20120295845
    Abstract: Compounds of formula (I) wherein: X is (A) or (B); Y is O or a bond; R1 is —C(O)—O—R3 or R2 is hydrogen, cyano, C1-C6 alkyl, or C3-C6 cycloalkyl; R5 is hydrogen, cyano, nitro, C1-C6 fluoroalkyl, C1-C6 alkyl, C1-C6 alkoxy, fluoroalkoxy, or C3-C6 cycloalkyl; R6 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, —C(O)—NH2, or C1-C6 alkyl substituted with hydroxy or C1-C6 alkoxy; m is 1 or 2, wherein when m is 1 then R8 is hydrogen, C1-C6 alkyl, —CH2—(C1-C5)haloalkyl, C3-C6 cycloalkyl, or C1-C6 alkyl substituted with hydroxy; and when m is 2 then each R8 is independently C1-C3 alkyl or —CH2—(C1—C2)haloalkyl; modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
    Type: Application
    Filed: November 16, 2010
    Publication date: November 22, 2012
    Inventors: Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson
  • Publication number: 20120157495
    Abstract: The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 24, 2012
    Publication date: June 21, 2012
    Inventors: Michael J. MUNCHHOF, Lawrence A. Reiter, Susan D. La Greca, Christopher S. Jones, Qifang Li
  • Patent number: 8148401
    Abstract: The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: April 3, 2012
    Assignee: Pfizer Inc.
    Inventors: Michael J. Munchhof, Lawrence A. Reiter, Susan D. La Greca, Christopher S. Jones, Qifang Li
  • Publication number: 20110020460
    Abstract: Compounds of Formula I that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
    Type: Application
    Filed: June 4, 2010
    Publication date: January 27, 2011
    Inventors: Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson
  • Patent number: 7842699
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: November 30, 2010
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Publication number: 20100285145
    Abstract: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
    Type: Application
    Filed: May 6, 2010
    Publication date: November 11, 2010
    Inventors: Etzer Darout, Michael P. DeNinno, Kentaro Futatsugi, Cristiano Guimaraes, Bruce A. Lefker, Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson
  • Publication number: 20100204119
    Abstract: The invention provides compounds of Formula (I), wherein R1, R2a, R2b, R3, m and A are as defined herein, as well as compositions thereof and methods for treating a disease, condition or disorder that is modulated by the inhibition of the diacylglycerol O-acyltransferase 1 (DGAT-1) enzyme by administering the compounds of the present invention and/or compositions thereof.
    Type: Application
    Filed: February 1, 2010
    Publication date: August 12, 2010
    Inventors: Gary E. Aspnes, Robert L. Dow, Michael J. Munchhof
  • Publication number: 20100197591
    Abstract: The invention provides compounds of the general Formula (I) where R1, R2, and A are defined herein, as well as the preparation, compositions and uses thereof.
    Type: Application
    Filed: February 1, 2010
    Publication date: August 5, 2010
    Inventors: Gary E. Aspnes, Robert L. Dow, Michael J. Munchhof
  • Publication number: 20100197590
    Abstract: The invention provides compounds of Formula (Ia) or pharmaceutically acceptable salts thereof, as well as the preparation, compositions and uses thereof, where R1, R2, R3, and m are defined as described above.
    Type: Application
    Filed: February 1, 2010
    Publication date: August 5, 2010
    Inventors: Robert L. Dow, Michael J. Munchhof
  • Patent number: RE41783
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: September 28, 2010
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof